FDA expands Anktiva to high-grade papillary-only bladder cancer after BCG failure
The FDA has expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin, or BCG, for adults with high-grade papillary-only bladder cancer that has not invaded the muscle layer and has not responded to BCG treatment. The decision gives clinicians the first FDA-approved option specifically for patients with BCG-unresponsive, high-grade papillary-only non-muscle invasive bladder cancer.
This is a notable regulatory shift because the agency did not rely only on a new stand-alone trial in papillary-only disease. Instead, it linked the expanded indication to earlier evidence in carcinoma in situ, or CIS, and to a body of laboratory and clinical data showing that CIS and high-grade papillary tumors share important biologic and histologic features. In practice, that means the FDA accepted a broader evidentiary bridge between two closely related forms of bladder cancer when one has already proven difficult to control after BCG.
Why the BCG-unresponsive setting leaves so few options
High-risk non-muscle invasive bladder cancer stays confined to the lining of the bladder, but the biology can still be aggressive. CIS appears as flat patches, while papillary tumors grow outward in finger-like projections. Both can be high-grade, and high-grade disease carries a greater risk of growth and spread than low-grade disease.
BCG remains a central bladder-sparing treatment because it activates local immune activity inside the bladder. When the cancer persists or returns after that immunologic pressure, the disease enters a narrow therapeutic corridor. Surgery to remove part or all of the bladder remains an important option, but not every patient is ready for that step, and delaying it can carry real danger if the tumor continues to progress.
A single sentence captures the clinical stakes: once BCG fails, time spent searching for an effective bladder-sparing approach can narrow the window before metastatic spread.
How Anktiva now fits into treatment
Anktiva is administered directly into the bladder through a catheter, alongside BCG. The regimen begins with once-weekly dosing for six weeks, followed by additional treatment based on response. Therapy may continue for as long as 37 months, but it should stop if cancer persists after a second six-week course, if the disease returns or progresses, or if side effects become unacceptable.
Biologically, the strategy is straightforward: BCG primes local immune activity, while Anktiva adds another immune signal inside the bladder to sustain an antitumor response. In a disease where residual malignant cells can hide in the urothelial lining and re-emerge after initial treatment, the appeal of a second immune pathway is obvious. The FDA’s action reflects confidence that this combined approach can help some patients whose tumors were not controlled by BCG alone.
The CIS data that supported the expansion
The original CIS approval rested on a trial identified as NCT03022825, which evaluated 77 adults, some of whom also had papillary tumors. In that study, 62% achieved a complete response, meaning no high-grade cancer was detected during follow-up assessments. Among those who responded, 58% maintained the response for at least 12 months and 40% for at least 24 months.
Those durability figures mattered. In BCG-unresponsive bladder cancer, a brief remission does not solve the long-term problem if the tumor quickly returns or advances. A complete response that persists over months, and in some cases years, gives clinicians a more credible basis for bladder preservation while monitoring closely for recurrence.
The FDA then used those results, together with clinical and laboratory evidence, to justify expansion into high-grade papillary-only disease. The agency emphasized that CIS and high-grade papillary tumors often occur together, can be difficult to distinguish microscopically, and both carry high risk when BCG no longer works. In that setting, shared biology can support shared regulatory logic.
Safety profile and surgical caution remain central
The most common adverse effects and laboratory abnormalities included painful or frequent urination, urgent need to urinate, blood in the urine, urinary tract infections, muscle or joint pain, chills, fever, and increased blood levels of creatinine and potassium. These toxicities fit the local inflammatory nature of intravesical therapy, where immune activation in the bladder can produce brisk urinary symptoms and systemic flu-like effects.
The prescribing information also carries a serious warning: delaying surgery to remove all or part of the bladder can allow the cancer to spread to other parts of the body, and that spread can be fatal. That warning should sit beside any discussion of bladder-sparing treatment. An intravesical regimen may preserve the bladder for some patients, but it is not a substitute for timely reassessment when the cancer refuses to respond.
A regulatory template the FDA may reuse
Along with the approval, the FDA signaled that it is working toward finalizing draft guidance on developing drugs and biological products for BCG-unresponsive non-muscle invasive bladder cancer. The guidance is expected to address how evidence from CIS studies can support approval for high-grade papillary-only disease.
That approach could shape future development programs. For rare or difficult-to-study subgroups, regulators sometimes have to decide whether the biology is close enough to justify extrapolation from one cohort to another. Here, the agency effectively said that the overlap between CIS and high-grade papillary tumors is strong enough to extend a proven immunotherapy combination into a closely related clinical space.
The approval went to Altor BioScience, LLC. For patients and clinicians facing BCG-unresponsive high-grade papillary-only bladder cancer, the decision expands bladder-sparing choices, but it does not soften the need for close surveillance, prompt cystoscopic follow-up, and early surgical consultation when response falters.